Lack of Estrogen Receptor Associated with an Increased Response Rate to Cytotoxic Chemotherapy in Metastatic Breast Cancer?

  • M. E. Lippman
  • J. C. Allegra
Part of the Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer book series (RECENTCANCER, volume 71)


Recent advances in the management of metastatic breast cancer have led to a significant improvement in patient care. A variety of new kinds of endocrine therapy, such as antiestrogen administration or medical adrenalectomy with aminoglutethimide, have reduced the toxicity of endocrine therapy. The use of steroid receptor determinations has improved the selection of patients for endocrine therapy enormously, such that about 75% accuracy in patient assignment for or against endocrine therapy can be anticipated.


Estrogen Receptor Endocrine Therapy Metastatic Breast Cancer Cytotoxic Chemotherapy Amino Glutethimide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Allegra, J. C., Lippman, M. E., Thompson, E. B.: Estrogen receptor status is the most important prognostic variable in predicting response to endocrine therapy in metastatic breast cancer. Eur. J. Cancer (submitted)Google Scholar
  2. Allegra, J. C., Lippman, M. E., Thompson, E. B.: The frequency, distribution, and quantitative analysis of steroid hormone receptors in patients with breast cancer. Cancer Res. (submitted)Google Scholar
  3. Bonadonna, G., Rossi, A., Valagussa, P., Banti, A., Veronesi, U.: The CMF program for operable breast cancer with positive axillary nodes: Updated analysis on the disease free interval, site of relapse, and drug tolerance. Cancer 39, 2904–2915 (1977)PubMedCrossRefGoogle Scholar
  4. Fisher, B., Carbone, P., Economou, S. G., Frelick, R., Glass, A., Lerner, H., Redmond, C., Zelen, M., Band, P., Katryeh, D. L., Wolmark, N., Fisher, E. R.: L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N. Engl. J. Med. 292, 117–122 (1975)PubMedCrossRefGoogle Scholar
  5. Frenning, D. H., Kennedy, B. J., Vosika, J.: Correlation of estrogen receptors and response to chemotherapy in advanced breast cancer. Proc. Am. Soc. Clin. Oncol, Abstract C-162 (1978)Google Scholar
  6. Jonat, W., Maass, H.: Some comments on the necessity of receptor determination in human breast cancer. Cancer Res. (to be published)Google Scholar
  7. Knight, W. A., Livingston, R. B., Gregory, E. J., McGuire, W. L.: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 37, 4669–4671 (1977)PubMedGoogle Scholar
  8. Konior, G. S., Lippman, M. E., Johnson, G. E.: Correlation of glucorticoid receptor levels and complete remission duration in “poor prognosis” acute lymphoblastic leukemia. Proc. Am. Soc. Clin. Oncol., Abstract C-346 (1977)Google Scholar
  9. Lippman, M. E., Huff, K. K.: A demonstration of androgen and estrogen receptors in human breast cancer using a new protamine sulfate assay. Cancer 38, 868–874 (1976)PubMedCrossRefGoogle Scholar
  10. Lippman, M. E., Allegra, J. C., Thompson, E. B., Simon, R., Barlock, A., Green, L., Huff, K. K., Do, H. M. T., Aitken, S. C., Warren, R.: The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N. Engl. J. Med. 298, 1223–1228 (1978)PubMedCrossRefGoogle Scholar
  11. Mercer, W. D., Wahl, T. M., Carlson, C. A.: Identification of estrogen receptors in human breast cancer cells by immunofluorescence. Proc. Am. Soc. Clin. Pathol, Abstract No. 28 (1978)Google Scholar
  12. Meyer, J. S., Rao, B. R., Stevens, S. C., White, W. L.: Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication. Cancer 40, 2290–2298 (1977)PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • M. E. Lippman
    • 1
  • J. C. Allegra
    • 1
  1. 1.Medicine Branch, National Cancer InstituteNational Institutes of HealthBethesdaUSA

Personalised recommendations